J. Fabrycki

432 total citations
14 papers, 336 citations indexed

About

J. Fabrycki is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, J. Fabrycki has authored 14 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 6 papers in Hepatology and 3 papers in Molecular Biology. Recurrent topics in J. Fabrycki's work include Hepatitis C virus research (6 papers), Hepatitis B Virus Studies (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). J. Fabrycki is often cited by papers focused on Hepatitis C virus research (6 papers), Hepatitis B Virus Studies (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). J. Fabrycki collaborates with scholars based in New Zealand, Canada and United States. J. Fabrycki's co-authors include Dennis J. Carlo, Charles P. Lollo, Mariusz Banaszczyk, C. C. Coffin, Richard M. Bartholomew, Deborah Y. Kwoh, Steven W. Brostoff, Milind Deshpande, Avinash Phadke and Mingjun Huang and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Hepatology and Biochimica et Biophysica Acta (BBA) - General Subjects.

In The Last Decade

J. Fabrycki

13 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Fabrycki New Zealand 6 238 103 80 67 37 14 336
Duckhyang Shin South Korea 11 341 1.4× 60 0.6× 71 0.9× 124 1.9× 45 1.2× 16 464
Janet R. Phelps United States 5 294 1.2× 46 0.4× 31 0.4× 72 1.1× 101 2.7× 6 463
P.M. Frederik Netherlands 5 212 0.9× 63 0.6× 34 0.4× 45 0.7× 15 0.4× 9 362
Rachael Kenworthy United States 7 196 0.8× 20 0.2× 119 1.5× 86 1.3× 24 0.6× 7 332
Anna Zajakina Latvia 11 100 0.4× 37 0.4× 29 0.4× 42 0.6× 50 1.4× 34 286
Masato Fujino Japan 5 220 0.9× 97 0.9× 10 0.1× 82 1.2× 25 0.7× 7 332
Kazuki Hashiba Japan 7 368 1.5× 53 0.5× 22 0.3× 27 0.4× 57 1.5× 8 432
Michael A. Gelman United States 6 340 1.4× 18 0.2× 22 0.3× 25 0.4× 23 0.6× 7 490
Ingo Roehl Germany 9 413 1.7× 62 0.6× 105 1.3× 214 3.2× 78 2.1× 14 609
Erin K. Reagan United States 8 219 0.9× 25 0.2× 30 0.4× 27 0.4× 19 0.5× 13 319

Countries citing papers authored by J. Fabrycki

Since Specialization
Citations

This map shows the geographic impact of J. Fabrycki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Fabrycki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Fabrycki more than expected).

Fields of papers citing papers by J. Fabrycki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Fabrycki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Fabrycki. The network helps show where J. Fabrycki may publish in the future.

Co-authorship network of co-authors of J. Fabrycki

This figure shows the co-authorship network connecting the top 25 collaborators of J. Fabrycki. A scholar is included among the top collaborators of J. Fabrycki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Fabrycki. J. Fabrycki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Huang, Mingjun, Wengang Yang, Steven D. Podos, et al.. (2017). Inhibition of complement alternative pathway by ACH-4471, the first clinical investigational orally-administered inhibitor of complement factor D. Molecular Immunology. 89. 200–201.
2.
Thanassi, Jane A., Guangwei Yang, Manuel Galvan, et al.. (2016). Comparison of complement functional assays: Differential sensitivities of hemolysis and Wieslab assays to levels of complement proteins C5, factor B, and factor D. Immunobiology. 221(10). 1169–1169. 1 indexed citations
3.
4.
Yang, Guo‐Min, Yanan Zhao, J. Fabrycki, et al.. (2013). 1199 FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1a HCV AND RESISTANT VARIANTS. Journal of Hepatology. 58. S487–S488. 1 indexed citations
5.
Yang, Wengang, Yongnian Sun, Xiaohong Hou, et al.. (2013). ACH-806, an NS4A Antagonist, Inhibits Hepatitis C Virus Replication by Altering the Composition of Viral Replication Complexes. Antimicrobial Agents and Chemotherapy. 57(7). 3168–3177. 9 indexed citations
6.
Fabrycki, J., Guanghua Yang, Yonggang Zhao, et al.. (2012). 1182 CHARACTERIZATION OF HCV NS3 PROTEASE VARIANTS FROM PATIENTS ENROLLED IN A 28-DAY PHASE 2A TRIAL OF ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A/RBV. Journal of Hepatology. 56. S468–S468. 5 indexed citations
7.
Yang, Guo‐Min, Jason A. Wiles, Yanan Zhao, et al.. (2012). 845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS. Journal of Hepatology. 56. S330–S330. 14 indexed citations
8.
Huang, Meng, Grace Yang, Yue Zhao, et al.. (2011). 1212 ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS. Journal of Hepatology. 54. S479–S479. 8 indexed citations
9.
Huang, Meei‐Li, J. Fabrycki, Steven D. Podos, et al.. (2010). 650 ANTIVIRAL ACTIVITY, COMBINATION AND RESISTANCE OF ACH-1625, A POTENT, CLINICAL STAGE HCV NS3 PROTEASE INHIBITOR. Journal of Hepatology. 52. S254–S254. 2 indexed citations
10.
Sanchez, Amy, Dongmei Liu, Xiaohong Hou, et al.. (2008). A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery. Journal of Virological Methods. 151(1). 154–157. 3 indexed citations
11.
Yang, Wengang, J. Fabrycki, Xiaohong Hou, et al.. (2008). Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors. Antimicrobial Agents and Chemotherapy. 52(6). 2043–2052. 35 indexed citations
12.
Huang, Min, Wenhui Yang, J. Fabrycki, et al.. (2007). [13] IN VITRO EVALUATION OF COMBINATION TREATMENT OF ACH-806 WITH INTERFERON; VX-950 AND NM 107. Journal of Hepatology. 46. S8–S8. 2 indexed citations
13.
Lollo, Charles P., Mariusz Banaszczyk, J. Fabrycki, et al.. (2000). Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo. Biochimica et Biophysica Acta (BBA) - General Subjects. 1523(1). 103–110. 44 indexed citations
14.
Kwoh, Deborah Y., C. C. Coffin, Charles P. Lollo, et al.. (1999). Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1444(2). 171–190. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Duckhyang Shin Breakdown of academic impact, for papers by Janet R. Phelps Breakdown of academic impact, for papers by P.M. Frederik Breakdown of academic impact, for papers by Rachael Kenworthy Breakdown of academic impact, for papers by Anna Zajakina Breakdown of academic impact, for papers by Masato Fujino Breakdown of academic impact, for papers by Kazuki Hashiba Breakdown of academic impact, for papers by Michael A. Gelman Breakdown of academic impact, for papers by Ingo Roehl Breakdown of academic impact, for papers by Erin K. Reagan
Rankless by CCL
2026